diagnost tool
price close busi februari
fast-grow compani anim health
diagnost seek take modest us market
share gain expand intern time
dog day level
expect cut estim pt stick buy
call wors could imagin direct right
lower estim last week magnitud miss weak
guid caught us off-guard execut dismal warn last
week look like mark third consecut bridg year investor hope
huge count surprisingli maintain lt revenu
target impli drive revenue growth look imposs absent
signific acquisit possibl see path
om target given ramp spend also unclear cash
need undergo strateg shift requir spend said think
may make invest satisfi wish one prospect
buyer action remind us abaxi strateg pivot year
takeout zoeti buy thesi materi challeng ratchet
estim lower pt stick buy rate
miss rev y/i miss
ep miss companion rev
miss consum rev y/i miss
part due slower-than-expect instal larg new custom
petvet center new issu surpris resolv
imag rev declin y/i vs new equin product push
indic vet jitteri decemb stock market implod
guid guid rev mark straight year revenu declin
y/i /street guid core rev
rev y/i off-set non-cor rev
y/i compar non-cor rev rev
respect expect non-cor rev tick back think
merck restock roll high inventori core guid
growth consum vs prior target line
guid growth us imag rev growth ou imag rev
includ acquir franc busi
lower rev higher spend wipe away profit guid opex
y/i y/i higher spend anoth y/i higher
look hire rep vs prior given declin rev higher
spend guid om vs well prior
model lower rev lower gm
rais opex lower om sink ep
lower rev
well target announc analyst day last year
lt target add us reiter lt target rev
y/i om requir y/i margin expans rev
om revenu target could hit acquisit
fail see math work realiz long-term om goal even
speak manag today off-lin
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
stick buy rate quit disappoint compani
mention guid significantli lower
estim primarili relat lower estim non-cor
busi buy-thesi remain intact howev believ thesi
challeng given seem on-going stream diappoint oper
result multipl facet compani busi link takeaway
compani analyst day primari chang current think
think analyst day function lower revenu estim primarili
limit non-cor busi segment lower margin assumpt
push-out compani urine-fec instrument plan launch
combin instrument
lower price target lower pt use
multipl revenu estim discount
back year discount rate use million dilut share outstand
trade next year revenu point less expens
buy-rat nasdaq
catalyst launch rotor chemistri ou launch element
multiplex immunodiagnost analyz initi launch cortisol
news ou launch new tuck-in deal potenti new financ
event launch urine-fec uf analyz
ou expans recent tuck-in acquisit franc recent day
close acquisit optom france-bas compani design develop
manufactur distribut vet imag product primari focu endoscopi
optom gener rev million euro employe
acquir busi modest sum resourc give
busi beachhead franc see variou opportun across
europ similar other much larger view still
desir partner larg establish firm suspect potenti deal
indic presenc franc see
quit opportun ou bolt tuck-in tune rev
thu think like remain acquisit pay deal
cash remain question us option financ
view recent mention see opportun acquir
revenu one sever possibl deal ou busi build
australia month expect first revenu australia come
also target new partner middl east ukrain
eastern europ select asian countri doesnt coverag
zts/abax impact recent indic see chang field
result zts-abax merger suggest earli think abax
longer donor point share year point share donor
split zts/abax team bundl rotor therapeut
also opin acquir abaxi acceler abil test treat
larg anim health player could follow suit impli mar acquir vca antech
boehring ingelheim bi rev acquir merial anoth
global anim health compani like elanco merck bayer hillhous china
end user demand hold recent day ask strength
end-market vet clinic respons recent commentari databas
pet clinic shown declin pet offic visit indic continu
see good growth end market though suspicion may track
end user data close nasdaq buy
said obvious track consum growth level growth
grow albeit came expect though still indic good
recur revenu growth anim health diagnost despit slowdown offic
visit hypothesi declin foot traffic anim health clinic may
function pet owner tri busi via on-line channel
market share dynam recent day estim market share
anim health diagnost unit state abaxi
noth estim terribl differ
trail survey data suggest abaxi
buy unchang target price februari
diagnost tool
none/greenfield caution data come
survey respons time tini fraction clinic us
survey data also repres averag last three year like exclud
abaxi recent share loss recent share gain link
recent anim health survey found
move forward combin urin fecal analyz togeth onto one
platform part result combin two expect launch uf
mark delay rel time announc analyst day
compani origin commun urin fecal view
delay disappoint risk thesi top pick
investor need push growth box concern valid
compani earn call guid neg revenu growth
view risk thesi yet anoth bridg year next
year regardless think new product set nice futur growth inflect
think mark solid growth compani execut
intern expans benefit traction new product coupl
possibl market share gain unit state
element uf look provid automat imag annual urin sediment
exam manual point-of-car fecal flotat exam complet year
expect launch serv industri first dual urine-fec analyz
size combin opportun urin fecal
indic valid abil combin urin fecal onto one
analyz indic product launch near term
excit uf
hska near-term product launch includ element rc rotor-bas chemistri
analyz element multiplex immunodiagnost platform expect
launch note time analyst day
hska element rc analyz design primarili ou custom first-tim
user chemistri analyz element rc abil run test
rotor vs abaxi tests/rotor view competit advantag
compar legaci non-multiplex immunodiagnost platform element
lower cost faster higher sensit allow multiplex
intend launch element total cortisol assay
compris revenu flow legaci immunodiagnost box
intend launch test heartworm lyme anaplasma ehrlichia
like opinion view test opportun
roughli custom long-term subscript model six-year
term agreement tend monthli minimum
annual price escal target activ subscrib
indic corpor vet hospit us vs
nascent chines market point rise interest veterinari invest
china evidenc hillhous capit group one china largest ventur fund
acquisit chines vet hospit
buy unchang target price februari
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
diagnost tool
buy unchang target price februari
diagnost tool
